This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Editors' Note: Commenting on “Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study,” Galduróz and colleagues argue that the negative findings of the study may be related to a confusion of concepts such as impulsivity, compulsivity, and craving. Furthermore, Liang and colleagues suggest that some impulse control disorders may be more responsive to naltrexone than others. Authors Weintraub et al. respond. Sethi and Strowd discuss the challenges of modern electronic medicine.—Chafic Karam, MD, and Robert C. Griggs, MD
Papay et al.1 reported no significant effects of naltrexone in comparison to placebo to treat impulse control disorders (ICD) in Parkinson disease (PD). We suggest the results may be partially explained by problems with the outcome measures. The questionnaire used in the study …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Naltrexone for impulse control disorders in Parkinson disease
Impaired corticostriatal connectivity in impulse control disorders in Parkinson disease
Clinical features associated with impulse control disorders in Parkinson disease
Screening for impulse control symptoms in patients with de novo Parkinson disease